Jul 29, 2022 06:13 PM (GMT+8) · EqualOcean
The board of directors of CSPC Pharmaceutical Group (Chinese: 石药集团) together with its subsidiaries, is pleased to announce that "Docetaxel for Injection (albumin-bound)", a new drug developed by CSPC Zhongqi Pharmaceutical Technology (Chinese: 石药集团中奇制药技术有限公司). The product employs innovative human serum albumin encapsulation technology to deliver docetaxel in nanoparticles into patients. With this technology, the product will eliminate the need for premedication with hormone as required for all currently marketed docetaxel products, and will have no infusion related hypersensitivity reactions. The product can also significantly increase in vivo drug exposure and improve safety,efficacy and patient compliance.